December 18, 2020
For the initial evaluation of low-risk patients with stable chest pain, anatomic testing coronary CT angiography (CTA) with or without noninvasive fractional flow reserve (FFR) is cost-effective compared with functional testing, a new analysis based on PROMISE trial data indicates.
Over the course of a patient’s life, using CTA alone instead of functional testing would be cost-effective with an incremental cost-effectiveness ratio (ICER) of $2,743 per quality-adjusted life-year (QALY). Coronary CTA supplemented with noninvasive FFR (FFRCT) dominated functional testing, with greater effectiveness and less cost.
Researchers led by Júlia Karády, MD (Massachusetts General Hospital, Boston), report in